Monoclonal Antibody Therapy for Hematologic Malignancies

摘要: Monoclonal antibodies are a new class of agents that target tumor-associated antigens. Advances in hybridoma technologies the early 1980s allowed creation monoclonal with high specificity addition to development can be linked anticancer drugs, radioisotopes, or toxins. Several cancer-specific have received approval by United States Food and Drug Administration (FDA) many more currently under clinical investigation. This review summarizes either approved FDA for treatment hematologic malignancies. Rituximab, which targets CD20 antigen, has revolutionized B-cell lymphoma. The standard care front-line follicular center cell lymphoma diffuse large lymphomas, predominate two lymphomas Western world, is rituximab combined chemotherapy. Second-generation anti-CD20 being studied phase II III trials. Radioimmunotherapy also been second-line Additional immunoconjugates targeting variety B-cell-associated antigens clinic malignancies including CD22, CD23, CD80, CD40, CD30, CD4, CD37, CD74, CTLA-4, VEGF, insulin-like growth factor 1 receptor. We believe these will become